Editas Medicine, Inc.

Cambridge, Massachusetts, United States editasmedicine.com

Overview

Editas Medicine, Inc. is a leading genome editing company focused on translating the power and potential of CRISPR/Cas9 and CRISPR/Cpf1 technologies into a robust pipeline of medicines aimed at treating a broad range of serious diseases. The company is dedicated to harnessing the potential of these transformative technologies to develop medicines in the therapeutic areas of oncology, ophthalmology, and more.

Therapeutic areas

OphthalmologyOncologyGenetic Disorders

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Editas Medicine, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.

Related companies

BioMarin Pharmaceutical Inc.
United States
Biotech X Corporation
USA
Cellgen Diagnostics Inc.
United States
Genentech, Inc.
United States
Genetic Research Institute
USA
Novelna Inc.
United States
PTC Therapeutics, Inc.
United States
Rare Disease Research Global Inc.
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo